PetVivo Holdings Inc
Change company Symbol lookup
Select an option...
PETV PetVivo Holdings Inc
SABS SAB Biotherapeutics Inc
DIA SPDR® Dow Jones Industrial Average ETF Trust
SPY SPDR® S&P 500 ETF Trust
ABBNY Abb Ltd
FCF First Commonwealth Financial Corp
ARMN Aris Mining Corp
IBM International Business Machines Corp
JPM JPMorgan Chase & Co
GEHC GE Healthcare Technologies Inc
Go

Health Care : Health Care Equipment & Supplies | Small Cap Growth
Company profile

PetVivo Holdings, Inc. is a biomedical device company. The Company is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for animals. The Company’s lead product Spryng with OsteoCushion Technology, is a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The Company is primarily engaged in the business of commercializing and licensing products in the veterinary market to treat and/or manage afflictions of companion animals, such as dogs and horses. Its products are derived from biomaterials that simulate a body’s cellular tissue by virtue of their reliance upon natural protein and carbohydrate compositions, which incorporate such tissue building blocks as collagen, elastin, and proteoglycans such as heparin. The Company has a pipeline of therapeutic devices for both veterinary and human clinical applications.

Price
Delayed
$1.92
Day's Change
0.02 (1.05%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.92
Day's Low
1.92
Volume
(Light)

Today's volume of 320 shares is on pace to be much lighter than PETV's 10-day average volume of 5,516 shares.

320

Company Profile

PetVivo Holdings, Inc. is a biomedical device company. The Company is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for animals. The Company’s lead product Spryng with OsteoCushion Technology, is a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The Company is primarily engaged in the business of commercializing and licensing products in the veterinary market to treat and/or manage afflictions of companion animals, such as dogs and horses. Its products are derived from biomaterials that simulate a body’s cellular tissue by virtue of their reliance upon natural protein and carbohydrate compositions, which incorporate such tissue building blocks as collagen, elastin, and proteoglycans such as heparin. The Company has a pipeline of therapeutic devices for both veterinary and human clinical applications.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
26.78x
Price/Book (MRQ)
56.44x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

September 2023
Current Month
133.8K
Previous Month
129.2K
Percent of Float
1.66%
Days to Cover
7.9437 Days

Share Information

PETV is in a share class of common stock
Float
8.1M
Shares Outstanding
13.8M
Institutions Holding Shares
15
6.14%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Gregory D. Cash
  • John LaiPres.
  • Robert J. FolkesCFO
  • Randall A. MeyerCOO
  • John Fitzgerald Dolan

Address

  • 5251 Edina Industrial Blvd
  • Edina, MN 55439
  • Phone: (952) 217-4952
  • Fax: (775) 884-9383
  • https://petvivo.com/

Insider Trading

During the most recent quarter, 22K shares were bought in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.